Page 16 - Pharmaceutical Firms

Drug manufacturers in India benefit from Big Pharma interest beyond China

China has for nearly 20 years been the preferred location for a range of pharmaceutical research and manufacturing services due to the low cost and speed offered by contract drugmakers there

Aurobindo Pharma subsidiary receives USFDA approval for Ryzeneuta

It helps to enhance the immune function of cancer patients and prevent the side effects of neutropenia caused by chemotherapy

Pharma company Laurus Labs acquires 87.59% stake in Laurus Bio Private

The acquisition was made through a secondary purchase from the promoter group shareholders of Laurus Bio on November 20, 2023

Cipla's Pithampur unit gets USFDA warning; analysts remain bullish

On Monday, Cipla share price dropped 0.21 per cent, ending the day's trade at Rs 1,246 apiece on the BSE

Industry has potential to grow to $200 bn in value by 2030: Pharma Secy

The domestic pharmaceutical industry has the potential to grow by 4-5 times to around USD 200 billion in value terms by scaling up manufacturing and enhancing exports, a senior government official said on Friday. He noted that to reach a size of USD 200 billion by 2030 from around USD 50 billion currently, the industry needs to grow in double digits year-on-year while reducing dependence on imports and focussing on expanding exports. "The age of smart medicine is dawning upon us. The new therapies that will come to the fore in the next 20 to 30 years would deliver smart therapies virtually for every difficult illness that we know of today. We have to be ready for that age. We have to prepare for that age," Department of Pharmaceuticals Secretary Arunish Chawla said at a CII event here. He said the government is helping the industry with various policy initiatives, including production-linked incentives. "At USD 50 billion in 2020, we were a little over 10 per cent of our manufactur

Mankind Pharma sees 21% profit surge in Q2 despite consumer health hurdles

The delayed season not only affected anti-infectives but also related sub-therapies such as respiratory, cough and cold, gastro, and vitamins, says Juneja

Torrent, Zydus collaborate to bring liver disease treatment to India

Saroglitazar Mg received approval in March 2020 for NASH treatment and later expanded its indications to include NAFLD

Novavax plans to slash costs by another $300 mn amid sagging demand

Novavax shares rose 3.1% at 10:26 a.m. in New York after the company's third-quarter loss per share and revenue were better than analysts expected

Glenmark Pharmaceuticals receives USFDA approval for generic Prolixin

Prolixin is a prescription medication used to treat schizophrenia and other mental/mood disorders

Lupin's net profit jumps nearly four-fold on strong US growth, stock up

US sales cross $200 million for the first time in two years, beat analyst expectations

Lupin introduces generic version of Zemuron Injection in United States

The newly introduced Rocuronium Bromide Injection is available in two formulations

Cipla announces transfer of Generics Business Undertaking to subsidiary

The generics business contributed 9.95 per cent of Cipla's turnover and 0.92 per cent of its net worth in the financial year ended March 31, 2023

Alkem Laboratories posts 87.85% increase in PAT, sales in India up by 5%

On a sequential basis, the company exhibited a 16.26 per cent increase in revenue

Should touch Rs 1K crore from OTC this year, says Nandini Piramal

The benefit of having patented products contract manufacturing is that there is always growth, said Piramal

Gland Pharma Q2 result: Net profit fell 20% to Rs 194 cr on higher expenses

Gland Pharma reported a nearly 32% jump in revenue from operations to Rs 1,373 crore, driven by higher sales from the acquisition of the French pharmaceutical group Cenexi in January

Sun Pharmaceutical's vital signs: A strong dose of valuation multiples

The specialty segment and domestic business act as the lifeblood, coursing through the largest pharma company in the country, fuelling both revenue and margins

Lupin receives approval from the US FDA for its Selexipag for injection

In 2022, sales of the Selexipag Franchise in the US stood at $ 1.1 billion. The sales for January 1 to September 30, 2023, stood at $978 million

US sales momentum, margin gains to support pharma major Cipla's stock

Led by the US market which rose by 31 per cent, the company posted a 16 per cent growth in revenues

Pfizer Q2 results: Net profit declines 52% at Rs 149 cr, revenue slips 9.8%

Drug firm Pfizer Ltd on Saturday reported 52.11 per cent decline in net profit at Rs 148.96 crore for the second quarter ended September 2023. The company had logged a net profit of Rs 311.07 crore in July-September period a year ago, according to a regulatory filing by Pfizer. Revenue from operations declined 9.76 per cent to Rs 575.21 crore in the quarter as against Rs 637.47 crore in the year-ago period. Total expense was at Rs 410.76 crore, down 5.66 per cent. Total income was at Rs 611.28 crore in September quarter 2023-24, down 7.62 per cent.

Piramal Pharma clocks 11% revenue growth in quarter ending September

Company's Ebitda grows 44% year-on-year, Chairperson Nandini Piramal anticipates a stronger financial performance in H2